Trial Profile
A Phase 4 Multicenter, Open-Label, Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Pfizer
- 26 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Feb 2013 Planned end date changed from 1 Oct 2013 to 31 Oct 2013 as reported by Oregon Health and Science University Institutional Review Board.
- 05 Jan 2013 New source identified and integrated (IRB00008665: Oregon Health and Science University Institutional Review Board).